Will Morton

Dosimetry plays a central role in optimizing lutetium-177 (Lu-177) PSMA therapy, yet calculating it currently depends on post-therapy imaging.

Immunological priming before radiopharmaceutical therapy may enhance clinical efficacy without impairing prostate antigen-specific T cell response.

CCR2 is expressed in both atherosclerotic plaques and tumors.

Differentiating between fibrotic scarring and inflammation stages of disease is critical so that physicians can determine what treatment is best for the patient.

Understanding how and where certain brain connections are lost can help explain the symptoms patients experience.

The study confirms that deficits in M1 receptor are present in a subgroup of schizophrenia patients.

Fatigue, pain flare, nausea, and urinary symptoms are among the most commonly reported immediate side effects of Pluvicto therapy.

Abdominal aortic calcification (AAC) scores of 5 or higher were significantly associated with hip fractures.

By convention, most molecular imaging tracers such as F-18 FDG are injected one hour prior to PET scans to allow time for uptake of the tracer by tumors.

Gallium-68 (Ga-68)-prostate-specific membrane antigen (PSMA)-11 PET/CT can reduce the need for biopsies in men with suspected high-risk prostate cancer, according to a study published June 10 in Lancet Oncology.